ICH Q10
Every DSRV article whose Regulatory Snapshot cites ICH Q10: the enforcement case behind it, the inspection exposure it created, and what the desk would do about it.
- What has FDA cited under ICH Q10?
- 5 DSRV articles cite ICH Q10. Enforcement cases behind them: NAFDAC 5+5 Policy results published March 2026: 191 applications, 185 approved, 108 facility layouts cleared, 20 completed, 88 under construction. 58% first-time manufacturers; FDA Form 483 response practice and Warning Letter escalation patterns under 21 CFR Parts 210/211; FDA inspectional focus on CAPA and investigation adequacy under 21 CFR §211.192, with pharmaceutical quality system expectations set by ICH Q10; Deviation and investigation documentation expectations under 21 CFR §211.192 and quality system review practice per ICH Q10; Risk-proportionate control expectations under ICH Q9(R1) and pharmaceutical quality system principles in ICH Q10, applied to AI-assisted quality work. Inspection exposure across them: 3 high, 1 moderate, 1 low.
- What does DSRV recommend for ICH Q10?
- From the newest article (108 New Drug Facilities in Nigeria. Most Have Never Been Inspected.): NAFDAC approval confirms a facility was built. It does not confirm the quality system inside it is ready for WHO-PQ or FDA scrutiny. The 63 first-time manufacturers entering Nigeria's supply chain carry inspection risk proportional to their lack of prior GMP testing. DSRV is decision support, not legal advice; verify against the official source each article names.
- 6 min readHigh exposurecited as a tag
108 New Drug Facilities in Nigeria. Most Have Never Been Inspected.
NAFDAC's 5+5 Policy approved 108 new pharmaceutical manufacturing sites by early 2026. Sixty-three of them are first-time manufacturers with no inspection history, entering a supply chain where WHO prequalification assessments will test what local approval did not.
- Case
- NAFDAC 5+5 Policy results published March 2026: 191 applications, 185 approved, 108 facility layouts cleared, 20 completed, 88 under construction. 58% first-time manufacturers.
- DSRV take
- NAFDAC approval confirms a facility was built. It does not confirm the quality system inside it is ready for WHO-PQ or FDA scrutiny. The 63 first-time manufacturers entering Nigeria's supply chain carry inspection risk proportional to their lack of prior GMP testing.
- 7 min readHigh exposurecited as a tag
How to Respond to an FDA 483 Without Overcommitting
An FDA Form 483 lists inspectional observations, not final agency conclusions. The strongest responses are specific, evidence-led, and scoped — committing to what you can verifiably deliver rather than promising the world.
- Case
- FDA Form 483 response practice and Warning Letter escalation patterns under 21 CFR Parts 210/211.
- DSRV take
- A phased, evidence-backed commitment you can verifiably deliver beats a sweeping promise you will miss - the agency scores follow-through, not ambition.
- 8 min readHigh exposurecited as a tag
CAPA Response Strategy: What FDA Expects to See
A strong CAPA is more than a corrective fix — FDA expects a defensible root cause, a systemic corrective and preventive action, and a real effectiveness check. Here is how to structure one that holds up.
- Case
- FDA inspectional focus on CAPA and investigation adequacy under 21 CFR §211.192, with pharmaceutical quality system expectations set by ICH Q10.
- DSRV take
- A CAPA is only as defensible as the system-level cause it targets and the predefined effectiveness check that proves the fix worked.
- 6 min readModerate exposurecited as a tag
Reviewer-Style Questions for Deviation Reports
Before a deviation report leaves your desk, run it past the questions a quality reviewer or inspector will ask. This checklist turns self-review into a defensibility test.
- Case
- Deviation and investigation documentation expectations under 21 CFR §211.192 and quality system review practice per ICH Q10.
- DSRV take
- Every "no" on a reviewer-style pre-flight check is a question you will eventually have to answer - better now, with the team and evidence at hand, than during an inspection.
- 7 min readLow exposurecited as a tag
Where AI Can Safely Support Pharma Quality Teams
AI is most valuable in regulated quality work when it supports human judgment rather than replacing it. We map the tasks where AI adds real, low-risk leverage — and where the human must stay in control.
- Case
- Risk-proportionate control expectations under ICH Q9(R1) and pharmaceutical quality system principles in ICH Q10, applied to AI-assisted quality work.
- DSRV take
- AI belongs in preparation, pattern-surfacing, and pressure-testing - leverage for the quality team, with every regulated conclusion handed back to an accountable human.
Pressure-test your evidence before an inspector reads it
Bring the document that has to hold up under ICH Q10. DSRV maps the evidence, names the gaps, and routes judgment calls to human review. Controlled intake, no public file upload.
Regulatory intelligence and interpretation, not legal advice. Verify against the official FDA or ICH source each article names.